UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS

Neurology, 2020-08, Vol.95 (8), p.e943

2020

Volltextzugriff (PDF)

Progressive Neurochemical Abnormalities in Cognitive and Motor Subgroups of Amyotrophic Lateral Sclerosis: A Prospective Multicenter Study

Neurology, 2021-08, Vol.97 (8), p.e803

2021

Volltextzugriff (PDF)

Biomarkers and clinical trials in ALS

Journal of the neurological sciences, 2023-12, Vol.455, p.120979, Article 120979

Genge, Angela

2023

Volltextzugriff (PDF)

Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States

PloS one, 2022-06, Vol.17 (6), p.e0269154-e0269154

2022

Volltextzugriff (PDF)

Rate of speech decline in individuals with amyotrophic lateral sclerosis

Scientific reports, 2022-09, Vol.12 (1), p.15713-15713, Article 15713

2022

Volltextzugriff (PDF)

Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis

International journal of molecular sciences, 2023-03, Vol.24 (6), p.5065

2023

Volltextzugriff (PDF)

Involvement of the dentate nucleus in the pathophysiology of amyotrophic lateral sclerosis: A multi-center and multi-modal neuroimaging study

NeuroImage clinical, 2020-01, Vol.28, p.102385-102385, Article 102385

2020

Volltextzugriff (PDF)

Clinical studies in amyotrophic lateral sclerosis

Current opinion in neurology, 2022-10, Vol.35 (5), p.686-692

2022

Volltextzugriff (PDF)

Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging study

NeuroImage clinical, 2024-01, Vol.43, p.103633, Article 103633

2024

Volltextzugriff (PDF)

HERV-K inactive or potential pathogens from within?

Journal of the neurological sciences, 2021-04, Vol.423, p.117359-117359, Article 117359

2021

Volltextzugriff (PDF)

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

Neurology, 2019-06, Vol.92 (23), p.e2661

2019

Volltextzugriff (PDF)

Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio Syndrome

PM & R, 2015-07, Vol.7 (7), p.677-684

2015

Volltextzugriff (PDF)

Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada (P4-11.003)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Dysregulation of Adipocyte Response in Amyotrophic Lateral Sclerosis: Developing the Humanized in Vitro Model System to Screen for Immuno-metabolic Molecular Signatures (P5-11.001)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

A Pilot Study of Regular Home Use of Deep Lung Insufflation in Neuromuscular Patients With Mild to Moderate Restrictive Impairment

Chest, 2011-10, Vol.140 (4), p.687A-687A

2011

Volltextzugriff (PDF)

Feasibility of DBS screening to identify adult patients with Pompe disease in a neuromuscular clinic population

BMC musculoskeletal disorders, 2013-05, Vol.14 (S2), p.P1-P1, Article P1

Genge, Angela

2013

Volltextzugriff (PDF)

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Journal of the neurological sciences, 2023-12, Vol.455, p.121088, Article 121088

2023

Volltextzugriff (PDF)

Evaluating the Safety, Tolerability, and Pharmacokinetics of QRL-101 in Two Phase 1 Studies: QRL-101-01 in Healthy Adults and QRL-101-02 in Adults with ALS (P6-11.019)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

QRL-201-01—A Multi-center, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis (P6-11.010)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results (P6-4.001)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

Neurology, 2021-02, Vol.96 (6), p.e853

2021

Volltextzugriff (PDF)

Evaluating the safety, tolerability, and pharmacokinetics of QRL-101 in two phase 1 studies: QRL-101-01 in healthy adults and QRL-101-02 in adults with ALS

Journal of the neurological sciences, 2023-12, Vol.455, p.122737, Article 122737

2023

Volltextzugriff (PDF)

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

Journal of the neurological sciences, 2023-12, Vol.455, p.121718, Article 121718

2023

Volltextzugriff (PDF)

QRL-201-01: A multi-center, randomized, double-blind, placebo-controlled multiple ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis

Journal of the neurological sciences, 2023-12, Vol.455, p.122738, Article 122738

2023

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

KollektioneBooks on EBSCOhost

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(80)

Sprache

Englisch
(80)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(29)
Humans
(23)
Neurosciences & Neurology
(23)
Clinical Neurology
(20)
Amyotrophic Lateral Sclerosis
(15)
Male
(15)
Female
(14)
Middle Aged
(14)
Adult
(13)
Aged
(10)
Double-Blind Method
(8)
Neurosciences
(8)
Magnetic Resonance Imaging
(5)
Patients
(5)
Treatment Outcome
(5)
Amyotrophic Lateral Sclerosis - Drug Therapy
(4)
Aged, 80 And Over
(3)
Amyotrophic Lateral Sclerosis - Genetics
(3)
Amyotrophic Lateral Sclerosis - Pathology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials

A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS

Progressive Neurochemical Abnormalities in Cognitive and Motor Subgroups of Amyotrophic Lateral Sclerosis: A Prospective Multicenter Study

Biomarkers and clinical trials in ALS

Functional alterations in large-scale resting-state networks of amyotrophic lateral sclerosis: A multi-site study across Canada and the United States

Rate of speech decline in individuals with amyotrophic lateral sclerosis

Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis

Involvement of the dentate nucleus in the pathophysiology of amyotrophic lateral sclerosis: A multi-center and multi-modal neuroimaging study

Clinical studies in amyotrophic lateral sclerosis

Temporal and spatial progression of microstructural cerebral degeneration in ALS: A multicentre longitudinal diffusion tensor imaging study

HERV-K inactive or potential pathogens from within?

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio Syndrome

Cost-effectiveness Analysis of Efgartigimod Versus Chronic Intravenous Immunoglobulin (IVIg) for Treatment of Acetylcholine Receptor Antibody Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) in Canada (P4-11.003)

Dysregulation of Adipocyte Response in Amyotrophic Lateral Sclerosis: Developing the Humanized in Vitro Model System to Screen for Immuno-metabolic Molecular Signatures (P5-11.001)

A Pilot Study of Regular Home Use of Deep Lung Insufflation in Neuromuscular Patients With Mild to Moderate Restrictive Impairment

Feasibility of DBS screening to identify adult patients with Pompe disease in a neuromuscular clinic population

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Evaluating the Safety, Tolerability, and Pharmacokinetics of QRL-101 in Two Phase 1 Studies: QRL-101-01 in Healthy Adults and QRL-101-02 in Adults with ALS (P6-11.019)

QRL-201-01—A Multi-center, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis (P6-11.010)

Phase 3, Open-Label, Multicenter Safety Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (MT-1186-A01): 48-Week Results (P6-4.001)

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial

Evaluating the safety, tolerability, and pharmacokinetics of QRL-101 in two phase 1 studies: QRL-101-01 in healthy adults and QRL-101-02 in adults with ALS

Phase 3, open-label, multicenter safety study of oral edaravone in patients with amyotrophic lateral sclerosis (MT-1186-A01): 48-week results

QRL-201-01: A multi-center, randomized, double-blind, placebo-controlled multiple ascending dose study to evaluate the safety and tolerability of QRL-201 in amyotrophic lateral sclerosis

Aktive Filter

Suchergebnisse filtern